HRP20191194T1 - Biokatalitički sastav - Google Patents
Biokatalitički sastav Download PDFInfo
- Publication number
- HRP20191194T1 HRP20191194T1 HRP20191194TT HRP20191194T HRP20191194T1 HR P20191194 T1 HRP20191194 T1 HR P20191194T1 HR P20191194T T HRP20191194T T HR P20191194TT HR P20191194 T HRP20191194 T HR P20191194T HR P20191194 T1 HRP20191194 T1 HR P20191194T1
- Authority
- HR
- Croatia
- Prior art keywords
- enzyme
- protective layer
- nanoparticles
- composition
- fact
- Prior art date
Links
- 108090000790 Enzymes Proteins 0.000 claims 20
- 102000004190 Enzymes Human genes 0.000 claims 20
- 239000011241 protective layer Substances 0.000 claims 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 10
- 239000002105 nanoparticle Substances 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 239000000377 silicon dioxide Substances 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000002243 precursor Substances 0.000 claims 4
- 229910000077 silane Inorganic materials 0.000 claims 4
- 235000012239 silicon dioxide Nutrition 0.000 claims 4
- 108010093096 Immobilized Enzymes Proteins 0.000 claims 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 238000006068 polycondensation reaction Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000034012 Acid sphingomyelinase deficiency Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 101000595674 Homo sapiens Pituitary homeobox 3 Proteins 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 102000004195 Isomerases Human genes 0.000 claims 1
- 108090000769 Isomerases Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- 208000018501 Lymphatic disease Diseases 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102100036088 Pituitary homeobox 3 Human genes 0.000 claims 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 208000007824 Type A Niemann-Pick Disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000026753 anterior segment dysgenesis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 229910021432 inorganic complex Inorganic materials 0.000 claims 1
- 239000010410 layer Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000035484 reaction time Effects 0.000 claims 1
- 238000001338 self-assembly Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229910052719 titanium Inorganic materials 0.000 claims 1
- 239000010936 titanium Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
Claims (11)
1. Postupak proizvodnje sastava, sastav obuhvaćajući barem
kruti nosač,
funkcionalni sastavni dio, odabran od proteina i spoja u tipu proteina, pri čemu je protein i spoj u tipu proteina enzim,
zaštitni sloj za zaštitu enzima, putem barem djelomičnog ugrađivanja, i
barem jednu bi - funkcionalnu poprečnu sponu za vezanje enzima na površinu krutog nosača,
naznačen time da postupak obuhvaća korake da
je prvo barem jedan enzim imobiliziran na površini krutog nosača,
i da je zatim zaštitni sloj za zaštitu enzima, putem barem djelomičnog ugrađivanja enzima, izgrađen s građevnim blokovima od kojih su barem dio monomeri koji mogu djelovati međusobno i s imobiliziranim enzimom, pri čemu građevni blokovi grade zaštitni sloj putem poli – kondenzacije silicij dioksid prekursora u vodenastim uvjetima,
naznačen time da su silicij dioksid prekursori tri-alkoksi-silan i tetra-alkoksi-silan, i,
naznačen time da postupak obuhvaća daljnji korak, nakon vremenskog intervala specifične reakcije, zaustavljanja reakcije samosastavljanja zaštitnog materijala za izgradnju zaštitnog sloja s građevnim blokovima kako bi se dobio preferirani zaštitni sloj sa željenom debljinom,
naznačen time da je debljina zaštitnog sloja u rasponu od 1 do 25 nm i između 50% i 150% dužine duže osi barem jednog enzima.
2. Postupak prema zahtjevu 1, naznačen time da imobiliziran i zaštićen enzim ima a) povećanu aktivnost pod stresnim uvjetima u usporedbi sa slobodnim nezaštićenim enzimom; i/ili b) povećanu povrativost za korištenje u kontinuiranoj operaciji u usporedbi sa slobodnim nezaštićenim enzimom.
3. Sastav obuhvaćajući
kruti nosač,
barem jedan funkcionalni sastavni dio, odabran od proteina i spoja u tipu proteina, pri čemu je protein i spoj u tipu proteina enzim,
barem jednu bi - funkcionalnu poprečnu sponu za vezanje enzima na površinu krutog nosača i pri čemu je enzim imobiliziran na površini krutog nosača,
i zaštitni sloj za zaštitu enzima putem barem djelomičnog ugrađivanja,
naznačen time da je zaštitni sloj za zaštitu enzima sloj izgrađen s građevnim blokovima, monomerima koji mogu djelovati međusobno i s imobiliziranim enzimom,
naznačen time da građevni blokovi grade zaštitni sloj putem poli – kondenzacije silicij diokisid prekursora u vodenastim uvjetima, naznačen time da su silicij dioksid prekursori tri-alkoksi-silan i tetra-alkoksi-silan, i naznačen time da je debljina zaštitnog sloja u rasponu od 1 do 25 nm i između 50% i 150% dužine duže osi barem jednog enzima.
4. Sastav prema zahtjevu 3, naznačen time da imobiliziran i zaštićen enzim ima a) povećanu aktivnost pod stresnim uvjetima u usporedbi sa slobodnim nezaštićenim enzimom; i/ili b) povećanu povrativost za korištenje u kontinuiranoj operaciji u usporedbi sa slobodnim nezaštićenim enzimom.
5. Sastav prema zahtjevu 3, naznačen time da je kruti nosač nanočestica, posebice nanočestica odabrana iz grupe organskih nanočestica, anorganskih nanočestica, organski - anorganskih složenih nanočestica, samosastavljajućih organskih nanočestica, mezopornih silika nanočestica (SNP), zlatnih nanočestica, titanskih nanočestica.
6. Sastav prema zahtjevu 3 ili 5, naznačen time da je nosač određeni nosač, posebice s veličinom čestica do 100 µm, poželjno u rasponu između 20 i 1000 nm, osobito između 200 i 500nm, naročito između 300 i 400 nm.
7. Sastav u skladu s jednim od zahtjeva 3 – 6, naznačen time da je debljina zaštitnog sloja u rasponu od 1 nm do 20 nm, 1 nm do 15 nm, poželjno 5 nm do 15 nm.
8. Sastav u skladu s jednim od zahtjeva 3 – 7, naznačen time da je navedeni enzim odabran iz grupe koja se sastoji od oksidoreduktaza, transferaza, hidrolaza, liaza, izomeraza i/ili ligaza.
9. Korištenje sastava iz bilo kojeg od prethodnih zahtjeva u katalitičkom procesu.
10. Korištenje sastava u katalitičkom procesu iz zahtjeva 9, naznačeno time da je za vrijeme postupka sastav subjekt barem jedne drugačije pH vrijednosti od optimalne pH vrijednosti funkcionalnog sastavnog dijela, posebno na način da se pH vrijednost razlikuje za barem +/- 0,5 pH jedinica i/ili do +/- 5 pH jedinica od optimalne pH za funkcionalan sastavni dio i/ili kemijsko opterećenje; i/ili biološko opterećenje; i/ili otapala; i/ili fizikalno opeterećenje; i/ili povišene temperature, koje prelaze optimalnu temperaturu za funkcionalni sastavni dio za barem 5ºC; i/ili do 60ºC, posebice 50ºC, posebice 40ºC, posebice 30ºC, posebice 20ºC, posebice 10ºC, posebice 5ºC i/ili do smanjenih temperatura, koje odstupaju od optimalne temperature za funkcionalan sastavni dio za barem 5ºC; i/ili do 60ºC.
11. Sastav prema bilo kojem od prethodnih zahtjeva za korištenje u terapiji, posebno u terapiji jednog od sindroma manjka sfingomijelinaze (ASMD), Niemann-Pickove bolesti (NPD), poremećaja pohrane lizosoma, Gaucherove bolesti, Fabryeve bolesti, MPS I, MPS II, MPS VI, poremećaja zadržavanja glikogena tip II, raka, alergija, metaboličkih bolesti, kardiovaskularnih bolesti, autoimunih bolesti, bolesti živčanog sustava, limfatičkih bolesti i virusnih bolesti.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13178504 | 2013-07-30 | ||
| PCT/EP2014/066365 WO2015014888A1 (en) | 2013-07-30 | 2014-07-30 | Biocatalytical composition |
| EP14748154.3A EP3027750B1 (en) | 2013-07-30 | 2014-07-30 | Biocatalytical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191194T1 true HRP20191194T1 (hr) | 2019-10-04 |
Family
ID=48948235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191194TT HRP20191194T1 (hr) | 2013-07-30 | 2019-07-01 | Biokatalitički sastav |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160168559A1 (hr) |
| EP (1) | EP3027750B1 (hr) |
| JP (1) | JP6678103B6 (hr) |
| KR (1) | KR102231386B1 (hr) |
| CA (1) | CA2919942C (hr) |
| DK (1) | DK3027750T3 (hr) |
| ES (1) | ES2735025T3 (hr) |
| HR (1) | HRP20191194T1 (hr) |
| HU (1) | HUE044039T2 (hr) |
| PL (1) | PL3027750T3 (hr) |
| PT (1) | PT3027750T (hr) |
| WO (1) | WO2015014888A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11795483B2 (en) * | 2016-12-15 | 2023-10-24 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Self-assembled nanoplatelet-enzyme bioconjugates providing for increased biocatalytic efficiency |
| CN107306950B (zh) * | 2017-07-20 | 2020-02-21 | 浙江禾本科技有限公司 | 一种辛酰溴苯腈纳米缓释制剂及其制备方法与它的用途 |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| KR102241582B1 (ko) | 2019-05-07 | 2021-04-19 | 김오규 | 강 또는 댐의 용존산소량을 높이는 물순환장치 |
| WO2021009550A1 (en) * | 2019-07-18 | 2021-01-21 | Rhodia Brasil Ltda | Preparation of immobilized enzymes |
| US20230159964A1 (en) | 2020-05-07 | 2023-05-25 | Inofea Ag | Method to produce biocatalytical compositions |
| KR20240004307A (ko) | 2021-03-18 | 2024-01-11 | 이노페아 아게 | 면역리간드-페이로드 접합체의 생성을 위한 생체촉매 조성물 및 용도 |
| JP2024515111A (ja) * | 2021-04-22 | 2024-04-04 | ペルセオ ファーマ アーゲー | 官能化生体触媒組成物 |
| WO2023089035A1 (en) | 2021-11-18 | 2023-05-25 | Inofea Ag | Biocatalytical compositions |
| GB202118010D0 (en) | 2021-12-13 | 2022-01-26 | UCB Biopharma SRL | Method for detecting and/or quantifying crosslinks formed by transglutaminases |
| WO2023139150A1 (en) | 2022-01-20 | 2023-07-27 | Perseo Pharma Ag | Functionalized biocatalytical compositions |
| WO2024061861A1 (en) | 2022-09-22 | 2024-03-28 | Perseo Pharma Ag | Functionalized biocatalytical compositions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925686A (ja) * | 1982-07-30 | 1984-02-09 | Nitto Electric Ind Co Ltd | 固定化酵素及びその製造方法 |
| DE69232290T2 (de) * | 1991-10-07 | 2002-06-13 | Genencor Int | Umhüllte enzym enthaltende körnchen |
| US6268329B1 (en) * | 1998-06-30 | 2001-07-31 | Nouozymes A/S | Enzyme containing granule |
| US20070042507A1 (en) * | 2003-07-16 | 2007-02-22 | Tsang Shik C | Composite nanoparticles |
| US7642077B2 (en) * | 2003-12-08 | 2010-01-05 | Genencor International, Inc. | Biocomposite comprising co-precipitate of enzyme, silicate and polyamine |
| JP2008092816A (ja) * | 2006-10-06 | 2008-04-24 | Japan Science & Technology Agency | 耐熱性酵素の使用方法 |
| CN101497879B (zh) * | 2008-02-03 | 2012-03-21 | 中国科学院大连化学物理研究所 | 一种多孔整体材料固定化酶微反应器的制备方法 |
| KR20110126166A (ko) * | 2009-03-09 | 2011-11-22 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 장기 효과를 갖는 단백질 전달을 위한 단일 단백질 나노캡슐 |
| EP2486061A4 (en) * | 2009-10-06 | 2013-08-28 | Angiochem Inc | COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTICS |
| EP2431742A1 (en) * | 2010-09-16 | 2012-03-21 | Fachhochschule Nordwestschweiz | Preparation of a Molecular Recognition Element |
| WO2014011166A1 (en) * | 2012-07-11 | 2014-01-16 | Empire Technology Development Llc | Methods and compositions for reducing bisphenol a release |
-
2014
- 2014-07-30 EP EP14748154.3A patent/EP3027750B1/en active Active
- 2014-07-30 WO PCT/EP2014/066365 patent/WO2015014888A1/en active Application Filing
- 2014-07-30 KR KR1020167004151A patent/KR102231386B1/ko active IP Right Grant
- 2014-07-30 ES ES14748154T patent/ES2735025T3/es active Active
- 2014-07-30 HU HUE14748154A patent/HUE044039T2/hu unknown
- 2014-07-30 US US14/908,448 patent/US20160168559A1/en not_active Abandoned
- 2014-07-30 JP JP2016530514A patent/JP6678103B6/ja active Active
- 2014-07-30 PT PT14748154T patent/PT3027750T/pt unknown
- 2014-07-30 PL PL14748154T patent/PL3027750T3/pl unknown
- 2014-07-30 DK DK14748154.3T patent/DK3027750T3/da active
- 2014-07-30 CA CA2919942A patent/CA2919942C/en active Active
-
2019
- 2019-07-01 HR HRP20191194TT patent/HRP20191194T1/hr unknown
-
2023
- 2023-07-12 US US18/221,195 patent/US20240011011A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015014888A1 (en) | 2015-02-05 |
| JP6678103B2 (ja) | 2020-04-08 |
| KR102231386B1 (ko) | 2021-03-24 |
| US20240011011A1 (en) | 2024-01-11 |
| JP6678103B6 (ja) | 2020-05-20 |
| ES2735025T3 (es) | 2019-12-13 |
| JP2016531906A (ja) | 2016-10-13 |
| HUE044039T2 (hu) | 2019-09-30 |
| DK3027750T3 (da) | 2019-07-15 |
| CA2919942A1 (en) | 2015-02-05 |
| PL3027750T3 (pl) | 2019-09-30 |
| PT3027750T (pt) | 2019-06-28 |
| KR20160037944A (ko) | 2016-04-06 |
| CA2919942C (en) | 2023-04-04 |
| US20160168559A1 (en) | 2016-06-16 |
| EP3027750B1 (en) | 2019-04-03 |
| EP3027750A1 (en) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191194T1 (hr) | Biokatalitički sastav | |
| Maleki et al. | Magnetic cellulose/Ag as a novel eco-friendly nanobiocomposite to catalyze synthesis of chromene-linked nicotinonitriles | |
| Cho et al. | Investigation of the interactions between ligand-stabilized gold nanoparticles and polyelectrolyte multilayer films | |
| WO2011071343A3 (ko) | 라만 활성분자가 나노입자 이합체의 접합부에 위치한 이합체 코어쉘 나노 입자, 이의 용도 및 이의 제조방법 | |
| WO2010111347A3 (en) | Microencapsulation of bioactive substances and methods of making the same | |
| WO2011082156A3 (en) | Organic particulate loaded polishing pads and method of making and using the same | |
| BRPI0922914A2 (pt) | processo de carbonilação catalisadores de modernita de cobre e/ou prata ligada | |
| WO2011081787A3 (en) | Sustained-release silica microcapsules | |
| WO2009018035A3 (en) | Drug eluting medical devices having porous layers | |
| BRPI0922353A2 (pt) | Derivados de n-{[(1r,4s, 6r-3- (2-piridinilcarbonil) - 3azabiciclo [4.1.0] hept-4-il] metil}-2-heteroarilamina e usos dos mesmos | |
| ATE494886T1 (de) | Verfahren zur herstellung von mikrokapseln | |
| WO2007117401A3 (en) | Indoles and benzoimidazoles as modulators of the histamine h4 receptor | |
| WO2006137855A3 (en) | Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility | |
| JP2009538358A5 (hr) | ||
| TWI348880B (en) | Microelectronic device including bridging interconnect to top conductive layer of passive embedded structure and method of making same | |
| EP2075064A4 (en) | SWAP LAYER CATALYST FOR THE PREPARATION OF ACRYLNITRILE AND METHOD FOR THE PRODUCTION OF ACRYLNITRILE | |
| WO2009109493A3 (en) | 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists | |
| WO2011044328A3 (en) | Methods to prepare patchy microparticles | |
| JP2012519374A5 (hr) | ||
| WO2015030966A3 (en) | Methods and systems for removing diamond-diamond bonding catalysts from polycrystalline diamond | |
| JP2018516755A5 (hr) | ||
| DE502007006189D1 (de) | Piezoaktor mit mehrschicht-verkapselung und verfahren zu seiner herstellung | |
| WO2011021794A3 (ko) | 탄소나노튜브-금속입자 복합 조성물 및 이를 이용한 발열 조향핸들 | |
| JP2011222495A5 (hr) | ||
| MX2010009820A (es) | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. |